Engineered flavoproteins as bioorthogonal photo-triggers for the activation of metal-based anticancer prodrugs

Chem Commun (Camb). 2023 Apr 18;59(32):4754-4757. doi: 10.1039/d2cc06363h.

Abstract

A multifunctional hybrid constructed for controlling the delivery and activation of Pt anticancer agents in vitro is described herein. We employed consensus tetratricopeptide repeat protein (CTPR) for the covalent co-anchoring of riboflavin (photocatalyst) and a Pt(IV) prodrug complex. The Pt-loaded flavoprotein induced a 40% reduction in PANC-1 cell viability as a result of the photocatalytic formation of cisplatin.

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Cell Line, Tumor
  • Cisplatin
  • Flavoproteins
  • Prodrugs* / pharmacology
  • Riboflavin / pharmacology

Substances

  • Prodrugs
  • Flavoproteins
  • Cisplatin
  • Antineoplastic Agents
  • Riboflavin